Infections Associated with Bendamustine and Anti-CD20 Antibody in Untreated Follicular Lymphoma: a Real-world Study

Overview

Journal J Clin Exp Hematop

Specialties Hematology
Pathology

Date 2023 Jul 30

PMID 37518273

Authors

Masuho Saburi

Kazuki Okuhiro

Natsumi Yoshida

Takami Haruyama

Yui Moroga

Yuka Yanai

Kazuhito Itani

Kuniko Takano

Shuhei Honda

Keiji Ono

Manami Iwanaga

Hitohiro Sasaki

Miyuki Abe

Kazuhiro Kohno

Toshiyuki Nakayama

Eiichi Ohtsuka

Masao Ogata

Affiliations

Soon will be listed here.

Citing Articles

Cytomegalovirus Occurrence and Time-to-onset Analysis Under Bendamustine With Anti-CD20 Antibodies Using the JADER Database.

Ito K, Koseki T, Morisaku M, Yamada S, Hayakawa N In Vivo. 2024; 38(2):923-927.

PMID: 38418128 PMC: 10905466. DOI: 10.21873/invivo.13520.

References

Galusic D, Basic-Kinda S, Pijuk A, Milunovic V, Dreta B, Franjic N . Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases. Hemasphere. 2022; 6(12):e807. PMC: 9668548. DOI: 10.1097/HS9.0000000000000807. View

Yamasaki S, Kohno K, Kadowaki M, Takase K, Iwasaki H . Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine. Ann Hematol. 2017; 96(7):1215-1217. DOI: 10.1007/s00277-017-3005-y. View

Gafter-Gvili A, Polliack A . Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2015; 57(3):512-9. DOI: 10.3109/10428194.2015.1110748. View

Ardeshna K, Qian W, Smith P, Braganca N, Lowry L, Patrick P . Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014; 15(4):424-35. DOI: 10.1016/S1470-2045(14)70027-0. View

Hasegawa T, Aisa Y, Shimazaki K, Nakazato T . Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma. Ann Hematol. 2014; 94(3):515-7. DOI: 10.1007/s00277-014-2182-1. View

Derenzini E, Zinzani P, Cheson B . Bendamustine: role and evidence in lymphoma therapy, an overview. Leuk Lymphoma. 2013; 55(7):1471-8. DOI: 10.3109/10428194.2013.842986. View

Paszkiewicz-Kozik E, Hus I, Palka M, Debowska M, Konska A, Kotarska M . Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group. Adv Clin Exp Med. 2023; 32(1):131-136. DOI: 10.17219/acem/157290. View

Gil L, Kazmierczak M, Kroll-Balcerzak R, Komarnicki M . Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma. Med Oncol. 2014; 31(5):944. PMC: 4006123. DOI: 10.1007/s12032-014-0944-1. View

Hiddemann W, Barbui A, Canales M, Cannell P, Collins G, Durig J . Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018; 36(23):2395-2404. DOI: 10.1200/JCO.2017.76.8960. View

10.

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

11.

Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C . Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017; 377(14):1331-1344. DOI: 10.1056/NEJMoa1614598. View

12.

Rummel M, Niederle N, Maschmeyer G, Banat G, von Grunhagen U, Losem C . Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873):1203-10. DOI: 10.1016/S0140-6736(12)61763-2. View